Direxion Shares ETF Trust - Direxion mRNA ETF (MSGR)

Overview

The fund described focuses on investing in companies involved in the advancement and application of messenger RNA (mRNA) technology. It dedicates at least 80% of its assets to securities that are part of its benchmark index or to investments that share similar economic characteristics. This index comprises companies based in the United States, Canada, and Europe that are at the forefront of mRNA technology development. By concentrating its investments in this way, the fund aims to provide exposure to the performance of leading companies in this innovative biotechnology sector. It operates as a non-diversified fund, meaning it may invest more of its assets in a smaller number of issuers than a diversified fund would.

Products and Services

The primary product offered by this fund is its investment vehicle focused on mRNA technology. Below is a breakdown of the key characteristics:

• Investment in mRNA Technology Companies: The fund specializes in investing in companies that are pioneers in messenger RNA technology. These companies are involved in various aspects of mRNA research and development, from therapeutics to vaccines, and are recognized for their innovative approaches in biotechnology. By investing in companies across the United States, Canada, and Europe, the fund aims to capture a broad spectrum of advancements within this sector.
• Exposure to Index Performance: The investment strategy involves tracking an index composed of companies leading in the mRNA technology field. This index serves as a benchmark for the performance of the fund, providing investors with a gauge of how well the sector is doing. The fund's commitment to invest at least 80% of its assets in the securities comprising the index or similar economic substitutes ensures a focused yet highly specialized investment approach.
• Non-Diversified Fund Structure: Operating as a non-diversified fund, it takes on a more concentrated investment approach by placing a larger fraction of its assets in a limited number of issuers. This strategy can offer higher reward possibilities, albeit with potentially higher risks, owing to the focused exposure to the mRNA technology sector. It contrasts with diversified funds, which spread investments across a wider array of securities to mitigate risk.